These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33117517)

  • 1. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia.
    Johansson P; Dierichs L; Klein-Hitpass L; Bergmann AK; Möllmann M; Menninger S; Habenberger P; Klebl B; Siveke JT; Dührsen U; Choidas A; Dürig J
    Ther Adv Hematol; 2020; 11():2040620720933761. PubMed ID: 33117517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
    Frigault MM; Mithal A; Wong H; Stelte-Ludwig B; Mandava V; Huang X; Birkett J; Johnson AJ; Izumi R; Hamdy A
    Cancer Res Commun; 2023 Nov; 3(11):2268-2279. PubMed ID: 37882668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
    Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.
    Brisard D; Eckerdt F; Marsh LA; Blyth GT; Jain S; Cristofanilli M; Horiuchi D; Platanias LC
    Oncotarget; 2018 Dec; 9(99):37305-37318. PubMed ID: 30647871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
    Göthert JR; Imsak R; Möllmann M; Kesper S; Göbel M; Dührsen U; Scholz A; Lücking U; Baumann M; Unger A; Schultz-Fademrecht C; Klebl B; Eickhoff J; Choidas A; Dürig J
    Oncotarget; 2018 May; 9(41):26353-26369. PubMed ID: 29899864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway.
    Ni W; Zhang F; Zheng L; Wang L; Liang Y; Ding Y; Yik JHN; Haudenschild DR; Fan S; Hu Z
    Front Cell Dev Biol; 2020; 8():579658. PubMed ID: 33015073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.
    He L; Tang J; Andersson EI; Timonen S; Koschmieder S; Wennerberg K; Mustjoki S; Aittokallio T
    Cancer Res; 2018 May; 78(9):2407-2418. PubMed ID: 29483097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do novo del(9)(p13) in a childhood T-cell prolymphocytic leukemia as sole abnormality.
    Wafa A; Aljapawe A; Othman MA; Liehr T; Alhourani E; Al Achkar W
    Exp Hematol Oncol; 2014; 3():28. PubMed ID: 25954594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
    Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Rahman R; Rahaman MH; Hanson AR; Choo N; Xie J; Townley SL; Shrestha R; Hassankhani R; Islam S; Ramm S; Simpson KJ; Risbridger GP; Best G; Centenera MM; Balk SP; Kichenadasse G; Taylor RA; Butler LM; Tilley WD; Conn SJ; Lawrence MG; Wang S; Selth LA
    Br J Cancer; 2024 Oct; 131(6):1092-1105. PubMed ID: 39117800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
    Yin T; Lallena MJ; Kreklau EL; Fales KR; Carballares S; Torrres R; Wishart GN; Ajamie RT; Cronier DM; Iversen PW; Meier TI; Foreman RT; Zeckner D; Sissons SE; Halstead BW; Lin AB; Donoho GP; Qian Y; Li S; Wu S; Aggarwal A; Ye XS; Starling JJ; Gaynor RB; de Dios A; Du J
    Mol Cancer Ther; 2014 Jun; 13(6):1442-56. PubMed ID: 24688048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
    Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
    PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses.
    von Jan J; Timonen S; Braun T; Jiang Q; Ianevski A; Peng Y; McConnell K; Sindaco P; Müller TA; Pützer S; Klepzig H; Jungherz D; Dechow A; Wahnschaffe L; Giri AK; Kankainen M; Kuusanmäki H; Neubauer HA; Moriggl RH; Mazzeo P; Schmidt N; Koch R; Hallek MJ; Chebel A; Armisen D; Genestier L; Bachy E; Mishra A; Schrader A; Aittokallio T; Mustjoki S; Herling M
    Blood; 2024 Jun; ():. PubMed ID: 38941598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.